CELL & GENE CAPACITY UPDATE VIDEOS
Minaris Advanced Therapies Capabilities Update March 2026: Cell & Gene Therapy
A global CDMO specializing in cell and gene therapies, offering end-to-end development, manufacturing, and testing services with over 25 years of expertise and personalized client support.
Lonza Capabilities Update March 2026: Cell & Gene Therapy
A global CDMO outlines end-to-end capabilities in cell and gene therapy, mRNA, and microbial platforms, emphasizing scalability, innovation, and seamless development through commercial manufacturing.
Landmark Bio Capabilities Update March 2026: Cell & Gene Therapy
A translational CDMO approach integrates development, analytics, and GMP manufacturing to streamline cell and gene therapy advancement from early research through scalable clinical production.
Comprehensive Cell Solutions Capabilities Update March 2026: Cell & Gene Therapy
An integrated draw‑to‑thaw CDMO model connecting donor sourcing, development, GMP manufacturing, and cryogenic storage to streamline workflows, strengthen quality control, and speed clinical readiness.
ElevateBio Capabilities Update March 2026: Cell & Gene Therapy
Learn how to embed process development expertise early and continuously to eliminate knowledge gaps, reduce risk, and ensure consistent, high-quality execution from transfer through manufacturing.
The Future Of Lentiviral Vector Innovation And Access
Founded on lentiviral vector design and manufacturing excellence, VBM and the LENTIVERSE™ technology platform provide a full suite of tools to quickly deliver state-of-the-art therapies and develop next-generation products.
Minaris Advanced Therapies Capacity Update October 2025: Cell & Gene Therapy
During this session, we will provide an overview of our capabilities, including our contract testing services, and an update on our current capacity.
Ascend & ABL Inc. Capacity Update October 2025: Cell & Gene Therapy
Operating from state-of-the-art GMP facilities, we provide end-to-end services to commercial, academic, and government clients, spanning process innovation through development, GMP manufacturing, QC testing, to aseptic fill/finish.
Andelyn Biosciences Capacity Update October 2025: Cell & Gene Therapy
A risk-based framework for identity testing of ancillary raw materials in gene therapy is presented, with emphasis on implementation based on product contact, material classification, and manufacturing stage.
Viralgen Capacity Update July 2025: Cell & Gene Therapy
As a leading CDMO in AAV manufacturing, Viralgen facilitates rapid transition to cGMP with a proven platform and an impeccable 100% IND success rate. Discover how Viralgen drives industry progress.
Minaris Advanced Therapies Capacity Update July 2025: Cell & Gene Therapy
With a robust track record of more than 7,500 GMP batches and proven platforms for multiple modalities, Minaris delivers speed, scalability, and reliability to help therapeutic developers bring cures to patients faster.
Excellos Capacity Update July 2025: Cell & Gene Therapy
Excellos leverages its extensive starting material expertise as a key differentiator. Explore how our deep understanding of partner-sourced raw materials, quality control, and supply chain management creates significant value for our clients.
A Concept-To-Commercial Gene Therapy CDMO
The Curator™ adherent platform has been used to manufacture more than 450 Phase 1 and 2 clinical batches, spanning over 17 years and covering a variety of serotypes and indications.
Agenda & Presenter Details
Visit our registration pages to see the current agenda and our list of presenting sponsors.
How can we help?
Are you a supplier looking to present at our next event?